S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports

NEW YORK, Feb. 26, 2015 /PRNewswire/ -- S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on MabVax Therapeutics Holdings Inc.

MabVax Therapeutics Holdings, Inc. (MBVX) is a clinical stage biotechnology company focused on the development of vaccine and antibody-based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. On May 12, 2014, the company, which was then known as Telik, Inc., entered into a merger agreement with MabVax Therapeutics, Inc., a privately held cancer immunotherapy company. On July 8, 2014, the parties completed the merger. Telik subsequently adopted the title MabVax Therapeutics Holdings, Inc.

MabVax generates its pipeline of antibody-based product candidates from patients who have been vaccinated with the propriety vaccines the company has licensed from Memorial Sloan-Kettering Cancer Center (MSKCC). The company believes that its approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform.

MabVax has concluded manufacturing agreements with Patheon to manufacture its lead antibody candidate, 5B1, under GMP conditions allowing MabVax to enter Phase I clinical trials in late-2015. The company has completed its preclinical development and evaluation program and believes that the study results justify its moving into GMP manufacturing and subsequent clinical development for this promising fully human monoclonal antibody.

MabVax has collaborated with Heidelberg Pharm to test an antibody drug conjugate using the company's 5B1 antibody and Heidelberg's linker and toxin technology in the treatment of pancreatic cancer. The results of both the in vitro and in vivo experiments are supportive of moving the project forward, according to MabVax.

The advanced preclinical study results of the company's work in tumor imaging using its lead antibody candidate, 5B1, conjugated to a radiolabel were published in the Journal of Nuclear Medicine. MabVax applied for and received a contract from the National Institutes of Health for the development of a next generation antibody based PET imaging agent for pancreatic cancer.

The company's therapeutic vaccines were developed at MSKCC and exclusively licensed to MabVax. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. A vaccine to address the orphan disease neuroblastoma has completed an initial Phase I trial at MSKCC yielding encouraging results. The vaccine product will be ready for a Phase II trial in the second half of 2015. MSKCC along with MabVax have completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, small cell lung cancer, and neuroblastoma over the last four years.

In the past year, MabVax has achieved full enrollment of both its sarcoma and ovarian cancer vaccine Phase II clinical trials. The company is following patients for assessment of the key overall survival (OS) endpoint. The company expects that a sufficient number of events will be reached in the first half of 2016 to allow for assessment of the OS endpoint. The company's discussions with FDA at the time MabVax developed the protocols for its vaccine trials indicated that the OS endpoint was the primary evaluation criteria for evaluation of the efficacy and safety of the vaccines.

The results of the Phase I trial with the company's neuroblastoma study were published in Clinical Cancer Research. MabVax states the study report describes a very encouraging result with a small cohort of difficult-to-treat patients who had repeatedly relapsed prior to beginning MabVax' treatment regimen. MabVax received an Orphan Drug Designation status for the neuroblastoma vaccine in September of 2014.

On September 10, 2014, MabVax announced that it had entered into agreements with MSKCC and Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully human antibodies discovered using the company's internally developed antibody discovery platform.

MabVax Therapeutics Holdings, Inc. is based in San Diego, California.

S&P Capital IQ's Factual Stock Report coverage on MabVax Therapeutics Holdings Inc will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.mabvax.com/ for additional information.

About S&P Capital IQ's Factual Stock Reports

Currently profiling approximately 400 issuers, S&P Capital IQ (MHFI) Factual Stock Reports increase market awareness of issuers in the investment community with insightful commentary, key statistics, and relevant corporate information.  The Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information on the covered companies to reach a wide spectrum of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the Reports also capture recent company developments, a financial review, key operating information, industry and peer comparisons, Street Consensus, performance charts, business summary, fundamental data, and timely news stories. Coverage of these reports is underwritten by the issuer, therefore S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

S&P Capital IQ Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations.  S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial (NYSE: MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need.  For more information, visit www.spcapitaliq.com.

In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies.

SOURCE S&P Capital IQ

Related Links

http://www.spcapitaliq.com